CagriSema vs. Tirzepatide:
A Comparative Analysis of Breakthrough Therapies for Obesity Management

Maple, K. and Monis, A.
Date: December 2024

Abstract

The escalating global prevalence of obesity underscores the urgent need for innovative and effective therapeutic interventions. Two promising treatments, **CagriSema**—a combination of semaglutide and cagrilintide—and **tirzepatide**, are emerging as front-runners in the fight against obesity. This white paper explores the efficacy, safety, and therapeutic potential of these cutting-edge treatments, drawing from current evidence. While both therapies demonstrate significant weight loss effects, limited head-to-head comparisons make it challenging to fully evaluate their relative advantages.

Current data suggest that CagriSema is among the most potent options for weight reduction, with some studies showing it outperforms tirzepatide. Systematic reviews and meta-analyses have revealed substantial body weight reductions with CagriSema compared to placebo and even other GLP-1 receptor agonists like tirzepatide. On the other hand, evidence also highlights tirzepatide's superior outcomes in certain contexts, particularly in glycemic control and weight loss at higher dosages. Mechanistic insights into these therapies reveal complementary pathways—GLP-1 receptor agonism, GIP receptor agonism, and amylin analogs—providing a robust foundation for their clinical applications.

Despite these promising findings, a lack of direct comparative studies limits our understanding of the nuanced differences between these therapies. Long-term data are especially scarce, leaving questions about sustained efficacy and safety unanswered. Bridging these research gaps is essential to optimize obesity management strategies and achieve the best possible patient outcomes. By advancing our understanding of these therapies, we move closer to tackling one of the most pressing public health challenges of our time.

Table of Contents

Introduction

Obesity, a complex and multifaceted condition, poses significant challenges to both weight management and metabolic health. As its prevalence continues to rise globally, the need for innovative therapies becomes increasingly urgent. Recent breakthroughs in pharmacotherapy have opened new doors, with glucagon-like peptide-1 receptor agonists (GLP-1RAs) and novel multi-receptor-targeting agents taking center stage. Among these, semaglutide, cagrilintide, and tirzepatide stand out as promising advancements in the battle against obesity.

Semaglutide, originally developed for type 2 diabetes, has captured attention for its powerful weight-loss potential. By stimulating insulin secretion, suppressing appetite, and slowing gastric emptying, it tackles some of the core drivers of obesity. These mechanisms make it a standout option in the pursuit of effective weight management.

Cagrilintide, a long-acting amylin analog, adds another dimension to this approach. By enhancing feelings of fullness and reducing calorie intake, it complements the effects of semaglutide. Together, these two drugs form the foundation of CagriSema, a combination therapy designed to harness their synergistic effects. Early research suggests CagriSema may deliver even greater results, potentially outperforming its individual components in both weight loss and glycemic control.

On a parallel path, tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, is breaking new ground. By targeting two receptors simultaneously, it amplifies the benefits typically seen with GLP-1RAs alone. This dual-action approach has shown promise in achieving dramatic weight loss, improved glycemic control, and better overall metabolic health.

This white paper dives into the comparative strengths of these emerging therapies, focusing on the combination of semaglutide and cagrilintide versus tirzepatide. By examining their efficacy

and safety, we aim to illuminate the potential of these groundbreaking treatments to redefine the future of obesity management.

Problem Statement

Obesity has evolved into a global health crisis, intricately linked to a host of chronic conditions including type 2 diabetes, metabolic syndrome, and cardiovascular disease. Despite the availability of diverse weight loss strategies, achieving sustainable and meaningful weight reduction remains a formidable challenge. Current treatments are often plagued by significant limitations, such as tolerability issues, a tendency for weight regain, and suboptimal efficacy. Many fail to address the intricate physiological mechanisms underlying obesity, underscoring the pressing need for innovative and effective therapies.

Recent advancements in pharmacotherapy have introduced promising options like semaglutide, cagrilintide, and tirzepatide. These agents represent a new frontier in obesity management by targeting key hormonal and metabolic pathways. However, their comparative effectiveness, safety profiles, and long-term viability remain areas of active investigation and debate.

The advent of CagriSema, a novel combination of semaglutide and cagrilintide, further enriches the evolving landscape of obesity treatments. By harnessing the complementary mechanisms of its components, CagriSema holds the potential to deliver superior outcomes. Yet, questions persist: How does CagriSema measure up against standalone therapies or multi-receptor agonists like tirzepatide? Can it effectively address the complex, multifactorial nature of obesity and provide sustainable, long-term results?

To optimize obesity management, it is essential to address these uncertainties. Rigorous exploration of the comparative efficacy, safety, and underlying mechanisms of these therapies will pave the way for more informed clinical decisions and innovative approaches to tackling this escalating public health challenge.

Recent studies exploring pharmacological interventions for obesity and weight management have concentrated on evaluating the safety, efficacy, and comparative outcomes of emerging therapeutic agents such as semaglutide, cagrilintide, and tirzepatide. These investigations provide valuable insights into the potential of these treatments to revolutionize obesity management, while also underscoring the need for further research to address gaps in knowledge.

H. Yao et al., for instance, conducted a systematic review and meta-analysis to evaluate the effectiveness of GLP-1 receptor agonists (GLP-1RAs) in weight reduction, glycemic control, and lipid profile modulation. Their work provides a foundational understanding of the benefits these therapies offer in addressing multiple facets of obesity and its associated conditions. Similarly, P. J. Rodriguez et al. carried out a cohort study comparing tirzepatide and semaglutide, focusing on weight loss outcomes and gastrointestinal side effects in overweight or obese individuals.

In an open-label phase 3 trial involving nearly 1,900 subjects, J.P. Frias et al. examined the comparative efficacy of tirzepatide and semaglutide over 40 weeks, revealing critical data on the

strengths and limitations of each treatment. Meanwhile, H.N. Jung and C.H. Jung reviewed clinical trials that highlighted the weight reduction and glycemic control capabilities of semaglutide and tirzepatide in individuals with type 2 diabetes.

Exploring more specialized contexts, M. Jamal et al. investigated the role of semaglutide and tirzepatide in preventing weight regain after sleeve gastrectomy. T. Karagiannis et al. focused on the subcutaneous administration of tirzepatide, emphasizing its effects on HbA1c levels and weight reduction in comparison to semaglutide. J.P. Frias et al. also studied the co-administration of semaglutide and cagrilintide in people with type 2 diabetes, primarily assessing their efficacy in supporting weight reduction.

Other studies broadened the scope of inquiry. M. Abdel-Malek et al. reviewed findings from pivotal trials such as SURMOUNT-1 and SURPASS-3, shedding light on dose-response relationships for tirzepatide, semaglutide, and cagrilintide. D.C.W. Lau et al. conducted a multicenter phase 2 trial to evaluate various doses of cagrilintide, focusing on its impact on body weight, safety, and tolerability. Lastly, P. Valdecantos et al. explored the combination of cagrilintide and tirzepatide in obese rats, uncovering potential synergistic effects in reducing food intake and promoting weight loss.

These studies collectively underscore the transformative potential of novel pharmacological strategies in weight management. At the same time, they highlight the critical importance of further exploration to refine therapeutic approaches and optimize outcomes for individuals battling obesity.

Methodology

The primary goal of this white paper was to investigate and compare the effectiveness of semaglutide and cagrilintide, both individually and in combination (CagriSema), with tirzepatide in promoting weight loss and improving related metabolic parameters. Given the limited availability of direct comparative studies, a curated selection of relevant research was included to bridge this gap and provide a comprehensive understanding of these treatments' individual and combined effects.

To align with this objective, studies were selected based on their focus on weight loss interventions involving semaglutide, cagrilintide, and tirzepatide. Emphasis was placed on research that assessed efficacy, safety, and mechanisms of action across diverse populations, including individuals with obesity and type 2 diabetes. The analysis incorporated systematic reviews, randomized clinical trials, cohort studies, and preclinical evaluations to ensure a robust and multidimensional perspective.

Although direct comparisons between semaglutide and cagrilintide versus tirzepatide remain scarce, the selected studies collectively provide valuable insights into their individual and combined roles in weight management. These investigations explore critical aspects such as dosing strategies, safety profiles, and therapeutic efficacy, offering a clearer understanding of how these treatments address obesity and its related metabolic disorders.

The methodology employed in this white paper prioritizes a holistic approach. By synthesizing data from diverse sources, this evaluation highlights the potential of CagriSema and tirzepatide to redefine obesity management. This comprehensive analysis not only identifies the strengths and limitations of these emerging therapies but also sets the stage for future research to optimize their application in clinical practice.

Results/Findings

The findings from these studies offer compelling insights into the evolving landscape of obesity pharmacotherapy, showcasing the remarkable potential of semaglutide, cagrilintide, tirzepatide, and their combinations. Among the most notable results is the efficacy of CagriSema—a combination of semaglutide and cagrilintide—which emerged as a standout therapy. In a meta-analysis by H. Yao et al., CagriSema was identified as the most effective GLP-1 receptor agonist for weight loss, even outperforming tirzepatide and other GLP-1RAs. Similarly, J.P. Frias and colleagues found that the co-administration of these two agents led to superior weight reduction and glycemic control compared to their use as standalone treatments, with significant results observed within 32 weeks.

Tirzepatide, another promising therapy, has consistently demonstrated robust outcomes. P.J. Rodriguez et al. revealed that patients treated with tirzepatide experienced greater weight loss compared to those on semaglutide, with notable changes observed as early as three months. This superiority was reinforced in a 40-week phase 3 trial led by J.P. Frias et al., where tirzepatide at various doses significantly outperformed semaglutide in reducing body weight while also offering improved glycemic control. Further evidence from the SURMOUNT-1 trial highlighted the dose-dependent effects of tirzepatide, with higher doses achieving weight reductions of up to 20.9% from baseline.

Semaglutide, while slightly overshadowed by tirzepatide in some comparisons, remains a powerful tool in weight management. Reviews of trials such as STEP 2 underline its efficacy in reducing body weight and improving metabolic parameters, making it a vital option for individuals with type 2 diabetes. Meanwhile, cagrilintide has also proven its value, with research by D.C.W. Lau et al. showing significant dose-dependent weight loss ranging from 6.0% to 10.8%. Importantly, this therapy was well-tolerated, with nausea being the most commonly reported side effect.

Studies focusing on specific populations, such as individuals managing weight recurrence after sleeve gastrectomy, further demonstrate the strengths of these therapies. Research by M. Jamal et al. showed that both semaglutide and tirzepatide significantly reduced weight in this group, with tirzepatide achieving a higher percentage of weight loss over six months. Preclinical findings by P. Valdecantos et al. add another dimension, revealing the synergistic potential of combining cagrilintide and tirzepatide to achieve greater weight loss in animal models.

Collectively, these findings paint a vivid picture of the potential impact of these therapies. Tirzepatide frequently stands out for its superior glycemic control and dramatic weight loss results, while CagriSema demonstrates exceptional synergy through its complementary mechanisms. As these treatments continue to redefine obesity management, further research

will be crucial to fully understand their long-term effects and optimize their clinical application. These advancements offer a glimpse of a brighter future, where obesity can be managed with precision and efficacy, transforming lives worldwide.

Discussion

The comparative analysis of the semaglutide and cagrilintide combination (CagriSema) and tirzepatide reveals compelling insights into their effectiveness, safety, and impact on glycemic control, highlighting their transformative potential in weight management. The studies reviewed in this white paper consistently underscore the superior performance of CagriSema in promoting weight loss when compared to other glucagon-like peptide-1 receptor agonists, including tirzepatide.

H. Yao et al.'s meta-analysis provides a pivotal finding: the combination of semaglutide and cagrilintide stands as the most effective GLP-1RA for weight reduction among 15 drugs studied, outperforming tirzepatide. This underscores the synergistic potential of combining semaglutide and cagrilintide, enabling outcomes that surpass those of tirzepatide monotherapy. Supporting this, P.J. Rodriguez et al. highlighted tirzepatide's superior weight loss benefits compared to semaglutide alone, but these findings fall short of the efficacy seen with CagriSema in comparable trials.

The impressive efficacy of tirzepatide was further validated by J.P. Frias et al. and M. Abdel-Malek et al., who demonstrated that it consistently achieves substantial weight loss across various doses and trials. Yet, findings from studies involving CagriSema suggest that its co-administration strategy enhances weight loss and glycemic control more effectively than either semaglutide or cagrilintide alone.

The broader applicability of tirzepatide was also highlighted in studies by H.N. Jung and M. Jamal et al., where it achieved significant weight loss in both type 2 diabetes patients and those managing weight recurrence after bariatric surgery. Karagiannis et al. further emphasized tirzepatide's strong performance in reducing HbA1c and weight, although they noted gastrointestinal side effects at higher doses, which may present a tolerability limitation.

Cagrilintide's individual contributions to weight loss were also noteworthy. Research by D.C.W. Lau et al. demonstrated dose-dependent and progressive weight loss with cagrilintide, with no plateau observed during the study period. M. Abdel-Malek et al. corroborated these findings, reporting consistent efficacy across doses, while preclinical research by Valdecantos et al. hinted at the potential for combining cagrilintide with tirzepatide to achieve even greater weight loss in animal models.

Collectively, these findings affirm the potential of CagriSema as a transformative strategy for weight management. Its dual mechanism of action leverages semaglutide's established efficacy while enhancing it with cagrilintide's ability to further promote satiety and caloric reduction. This synergy not only drives superior weight loss outcomes but also offers meaningful improvements in glycemic control, presenting a promising pathway for individuals battling obesity and metabolic disorders.

Despite the promising evidence, limitations remain. The lack of direct, head-to-head comparisons between CagriSema and tirzepatide constrains the ability to draw definitive conclusions about their relative performance. Robust, well-designed clinical trials are urgently needed to evaluate their long-term effectiveness, safety, and comparative advantages. Addressing these gaps will provide a clearer understanding of how best to integrate these therapies into clinical practice and maximize their potential for transforming obesity care.

Conclusion

The combination of semaglutide and cagrilintide (CagriSema) and tirzepatide represent significant advancements in the realm of weight management, offering not only profound benefits for weight loss but also meaningful improvements in glycemic control. This white paper has highlighted their transformative potential, particularly for individuals with obesity or type 2 diabetes, where existing treatments often fall short.

Current evidence positions CagriSema as the most effective intervention for weight loss, surpassing the performance of tirzepatide. The dual mechanism of action provided by semaglutide and cagrilintide—combining metabolic regulation with enhanced appetite suppression—sets a new benchmark in obesity pharmacotherapy, demonstrating synergistic effects that maximize clinical outcomes. These findings underscore the value of CagriSema in addressing the multifaceted challenges of obesity management.

Tirzepatide, while slightly less effective in weight reduction compared to CagriSema, remains a powerful and versatile option, particularly for individuals requiring substantial HbA1c reductions. Its consistent efficacy across various doses and populations reinforces its role as an important tool in the obesity treatment arsenal. However, higher doses of tirzepatide are associated with increased gastrointestinal side effects, which may limit tolerability in some patients.

Despite the promising potential of both therapies, key limitations remain. Chief among them is the lack of direct, head-to-head comparisons between CagriSema and tirzepatide, leaving questions about their relative performance unanswered. Furthermore, their long-term impact on weight maintenance, cardiovascular health, and overall quality of life remains an area for future investigation.

Continued research and development are essential to fully unlock the potential of these therapies. Robust clinical trials addressing their mechanisms of action, long-term safety, and optimal dosing strategies will be critical to refining treatment approaches and enhancing patient outcomes. As these therapies continue to evolve, they hold the promise of transforming the landscape of obesity management and improving the lives of millions worldwide.

References

Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. *BMJ*. 2024;384:e076410. Published 2024 Jan 29. doi:10.1136/bmj-2023-076410

Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. *JAMA Intern Med*. 2024;184(9):1056-1064. doi:10.1001/jamainternmed.2024.2525

Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. *N Engl J Med*. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519

Jung HN, Jung CH. The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?. *J Obes Metab Syndr*. 2022;31(1):28-36. doi:10.7570/jomes22012

Jamal M, Alhashemi M, Dsouza C, et al. Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study. *Obes Surg*. 2024;34(4):1324-1332. doi:10.1007/s11695-024-07137-0

Karagiannis T, Malandris K, Avgerinos I, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. *Diabetologia*. 2024;67(7):1206-1222. doi:10.1007/s00125-024-06144-1

Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. *Lancet*. 2023;402(10403):720-730. doi:10.1016/S0140-6736(23)01163-7

Abdel-Malek M, Yang L, Miras AD. Pharmacotherapy for chronic obesity management: a look into the future. *Intern Emerg Med*. 2023;18(4):1019-1030. doi:10.1007/s11739-023-03237-4

Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. *Lancet*. 2021;398(10317):2160-2172. doi:10.1016/S0140-6736(21)01751-7

Valdecantos P, Rada P, Ghosh S, et al. Beneficial effect of the combination therapy of cagrilintide, a dual amylin/calcitonin agonist, and tirzepatide, a dual GLP-1/GIP agonist, on body weight loss in obese rats. *Diabetes*. 2024;73(Supplement_1):300-OR. doi:10.2337/db24-300-OR

Appendices



Forest plot of network effect sizes between GLP-1RAs and placebo for weight loss.

Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. *BMJ*. 2024;384:e076410. Published 2024 Jan 29. doi:10.1136/bmj-2023-076410



Comparison of proportion of patients reaching weight loss targets of 5%, 10%, and 15% in STEP 2, SURPASS-1, and SURPASS-2.

Jung HN, Jung CH. The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?. *J Obes Metab Syndr*. 2022;31(1):28-36. doi:10.7570/jomes22012

Acknowledgments

The authors of this white paper wish to acknowledge Yao H, Rodriguez P.J, Frias J.P, Jung H.N, Jung C.H, Jamal M, Karagiannis T, Abdel-Malek M, Lau D.C.W, and Valdecantos P. for their extensive research and insights that have been instrumental in advancing the understanding of GLP-1RAs, tirzepatide, semaglutide and cagrilintide in weight management and metabolic health. This white paper relies heavily on their groundbreaking work, which has paved the way for future advancements in obesity pharmacotherapy.

Conflicts of Interest

Dr. Gluckman who was part of the study led by Rodriguez et al. reported consulting fees from Premier outside the submitted work.

Bergman B. who was part of the study led by Frias J.P. is employed by Eli Lilly.

J.P. Frias has received research funding from 89bio, Akero, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, and others and is involved with advisory boards and consulting for 89bio, Akero, Altimmune, Becton Dickenson, Boehringer Ingelheim, Carmot Therapeutics, Echosens, Eli Lilly, Gilead, Intercept, Merck, Novo Nordisk, Pfizer, and Sanofi.

Miras A.D, who contributed to a paper by Abdel-Malek M. et al, has received honoraria for educational events from Novo Nordisk, Astra Zeneca, Boehringer Ingelheim, Currax, Screen Health, and GI dynamics.

Lau D.C.W. is a consultant for and has received speaker honoraria from AstraZeneca, Amgen, Bausch Health, Boehringer Ingelheim, Eli Lilly, HLS Therapeutics, and Novo Nordisk, and has received research funding from AstraZeneca and Novo Nordisk.

Contact Information

For all questions and inquiries feel free to contact the authors directly.